IRCT20201223049816N1 IRCT 2021-01-11 Bagheiat-allah University of Medical Sciences Evaluation of the effectiveness of PHR-160 spray in hospitalized patients with Covid-19 Evaluation of the effectiveness of PHR-160 spray in hospitalized COVID-19 patients with severe lung involvement in improving oxygen saturation; a randomized clinical trial study 2020-12-20 anticipated 240 Complete https://irct.ir/trial/53342 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Data collection and data management will be done using electronic patient report forms and electronic data management system, and the steps of data cleaning and locking and data monitoring will be done on-line during the study.This set of forms is required for the initial assessment of the patient and the necessary examinations to determine the presence of COVID-19 disease and a checklist of exclusion and inclusion conditions. If patients are eligible to enter the study , they will enter the randomization stage and start the intervention. It is necessary to have this separate form set to prepare a Participant flow table according to the consort reporting standard. 1 covid-19. Intervention 1: Intervention group: 1. Phr-160 spray group: PHR spray:160 micrograms per puff, 1 puff every 1 hour up to ten times a day, on days 1 to 10 (use of Damir is required) in addition to the latest covid-19 treatment in the country protocol. Due to the clinical symptoms, this treatment protocol can be continued for 10 days if needed. Intervention 2: Control group: Standard emergency treatment based on protocol, Naproxen 250 mg , Famotidine 40 mg , Vitamin C 500 mg. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.